Health care and drug companies have been working together to make sure patients with pre-existing conditions have access to high-quality drugs, including generic versions of their own drugs.
The efforts are coming after more than a year of pressure from lawmakers, the U.S. Chamber of Commerce and others, who said drug companies should not be able to sell generic versions, and should not have to pay for it.
The Obama administration has urged drug companies to offer generic versions.
But the companies have resisted that push.
Health Care for America Now, a national consumer advocacy group, said it’s not uncommon for companies to have to negotiate prices with the government or with other companies.
They also have the ability to negotiate discounts and rebates, said Michael Taylor, the group’s senior vice president of government affairs.
That makes it easier for them to get discounts for their own customers.
The White House and other administration officials have said the drug companies’ incentives to use generic versions would hurt the broader public.
It’s unclear how much of a role generic drugs could play in improving access to medications.
Drugmakers also have lobbied against a federal law, which took effect in 2018, that would have required the drug makers to negotiate with health care providers when selling drugs, said Robert Langer, executive director of the advocacy group Physicians for a National Health Program.
But it hasn’t gone anywhere, Langer said.
Companies have been lobbying hard to get generic versions made, but the law hasn’t taken effect yet.
That means it’s unclear if drug companies will be able sell their own versions of generic drugs.
A study released this week by the National Center for Complementary and Alternative Medicine found that only about 3% of the generic drugs that have been approved by the Food and Drug Administration are being sold.
That compares to more than 35% of generic versions sold in 2014, according to a report by the advocacy organization, the Pharmaceutical Research and Manufacturers of America.
The study was based on more than 200 studies that were conducted between 2014 and 2016.
It found that most of the drugs were sold without generic labeling and without price protection.
The report said the industry was hoping to get the new law passed, but there were some issues.
Some lawmakers are pushing for legislation that would require drug companies and drug makers in particular to provide more information to consumers about the generic versions they are selling, the study found.
The Obama administration said the new rule would give Americans greater choices.
The administration has called for a public health initiative that would allow consumers to compare prices of a generic version of a drug with a brand-name version.